Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus short-course paclitaxel/platinum chemotherapy as first-line treatment for advanced or metastatic squamous non-small cell lung cancer
ChiCTR1900021726Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel, cisplatin and carboplatin in Pulmonary squamous cell carcinoma, sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free survival. Started Apr 2019; status: completed.
02
Drugs
sintilimabpaclitaxelcisplatincarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1900021726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021726.